Combined determination of plasma hyaluronan and the ratio of M2 monocyte/M1 monocyte ratio in breast cancer

doi:10.3969/j.issn.1673-8640.2019.02.005

Abstract

Abstract:

Objective To investigate the role of the combined determination of plasma hyaluronan（HA） and the ratio of M2 monocyte/M1 monocyte（M2/M1 ratio） in breast cancer. Methods A total of 98 patients with breast cancer（breast cancer group）,37 patients with breast benign diseases（breast benign disease group） and 41 healthy subjects（healthy control group） were enrolled. Plasma HA and carbohydrate antigen（CA）15-3 levels were determined by chemiluminescence. Flow cytometry was used to assess the expression of M1（CD14⁺CD163^-CD86⁺） and M2（CD14⁺CD163⁺CD204⁺） monocytes,and M2/M1 ratio was calculated. Correlation analysis was performed using Spearman correlation analysis. Receiver operating characteristic（ROC） curve was used to analyze the diagnostic efficiency of each marker. Results Plasma HA and CA15-3 levels,the proportion of M2 monocyte and M2/M1 ratio were higher in breast cancer group than those in breast benign disease and healthy control groups（P<0.05）,and there was no statistical significance between breast benign disease and healthy control groups（P>0.05）. There were correlations of HA with M2/M1 ratio and the proportions of M2 monocyte and M1 monocyte（r_s=0.401,0.393 and-0.189,P<0.05）. The area under ROC curve（AUC）,sensitivity and specificity of M2/M1 ratio for the diagnosis of breast cancer were higher than those of the other markers,and the combined determination of HA and M2/M1 ratio could improve the diagnostic efficiency of breast cancer. Plasma HA was correlated with the histological differentiation of breast cancer（P<0.05）,and M2/M1 ratio was correlated with tumor-node-metastasis（TNM） stage,histological differentiation,lymph node metastasis and estrogen receptor（ER）（P<0.05）. However,there was no relationship between CA15-3 and clinicopathological characteristics（P>0.05）. Conclusions The combined determination of HA and M2/M1 ratio plays a role in the auxiliary diagnosis of breast cancer.

Key words: Hyaluronan, Tumor-associated macrophage, Carbohydrate antigen 15-3, Breast cancer

CLC Number:

R446.1

ZHANG Boke, HUANG Yi, LIU Yiwen, HE Yiqing, YANG Cuixia, DU Yan, ZHANG Guoliang, GAO Feng. Combined determination of plasma hyaluronan and the ratio of M2 monocyte/M1 monocyte ratio in breast cancer[J]. Laboratory Medicine, 2019, 34(2): 116-121.

Figures/Tables 5

References 14

[1]	DUFFY M J,EVOY D,MCDERMOTT E W.CA 15-3:uses and limitation as a biomarker for breast cancer[J]. Clin Chim Acta,2010,411(23-24):1869-1874.
[2]	SOUSA S,BRION R,LINTUNEN M,et al.Human breast cancer cells educate macrophages toward the M2 activation status[J]. Breast Cancer Res,2015,17:101.
[3]	ROUSSOS E T,BALSAMO M,ALFORD S K,et al.Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer[J]. J Cell Sci,2011,124(Pt 13):2120-2131.
[4]	ADAMS D L,MARTIN S S,ALPAUGH R K,et al.Circulating giant macrophages as a potential biomarker of solid tumors[J]. Proc Natl Acad Sci U S A,2014,111(9):3514-3519.
[5]	SICA A,SCHIOPPA T,MANTOVANI A,et al.Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression:potential targets of anti-cancer therapy[J]. Eur J Cancer,2006,42(6):717-727.
[6]	ZHANG B,CAO M,HE Y,et al.Increased circulating M2-like monocytes in patients with breast cancer[J]. Tumour Biol,2017,39(6):1010428317711571.
[7]	WU M,CAO M,HE Y,et al.A novel role of low molecular weight hyaluronan in breast cancer metastasis[J]. FASEB J,2015,29(4):1290-1298.
[8]	TIAINEN S,TUMELIUS R,RILLA K,et al.High numbers of macrophages,especially M2-like(CD163-positive),correlate with hyaluronan accumulation and poor outcome in breast cancer[J]. Histopathology,2015,66(6):873-883.
[9]	MANTOVANI A,SOZZANI S,LOCATI M,et al.Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes[J]. Trends Immunol,2002,23(11):549-555.
[10]	MAEDA R,ISHII G,NERI S,et al.Circulating CD14+CD204+ cells predict postoperative recurrence in non-small-cell lung cancer patients[J]. J Thorac Oncol,2014,9(2):179-188.
[11]	LI C,LUO X,LIN Y,et al.A higher frequency of CD14+ CD169+ monocytes/macrophages in patients with colorectal cancer[J]. PLoS One,2015,10(10):e0141817.
[12]	OSTUNI R,KRATOCHVILL F,MURRAY P J,et al.Macrophages and cancer:from mechanisms to therapeutic implications[J]. Trends Immunol,2015,36(4):229-239.
[13]	CLAWSON G A,MATTERS G L,XIN P,et al.Macrophage-tumor cell fusions from peripheral blood of melanoma patients[J]. PLoS One,2015,10(8):e0134320.
[14]	KUANG D M,WU Y,CHEN N,et al.Tumor-derived hyaluronan induces formation of immunosuppressive macrophages through transient early activation of monocytes[J]. Blood,2007,110(2):587-595.

组别	例数	年龄（岁）	白细胞（×10⁹/L）	单核细胞（×10⁹/L）	HA（ng/mL）
乳腺癌组	98	50.50±10.19	5.79±1.65	0.35±0.10	71.25（55.79~96.08）
乳腺良性疾病组	37	49.35±8.26	5.86±1.18	0.36±0.13	49.36（43.83~56.13）^*
正常对照组	41	49.52±9.78	5.28±1.22	0.32±0.11	48.70（45.82~54.64）^*
组别	CA15-3（U/mL）		M1型单核细胞比例（%）	M2型单核细胞比例（%）	M2/M1比值
乳腺癌组	11.06（7.82~16.30）		30.85±5.52^#	5.71±1.52	0.193±0.070
乳腺良性疾病组	8.15（6.64~11.82）^*		39.11±4.97	3.90±0.98^*	0.087±0.028^*
正常对照组	9.82（6.75~12.09）^*		32.58±5.31^#	3.76±1.22^*	0.103±0.035^*

组别	例数	年龄（岁）	白细胞（×10⁹/L）	单核细胞（×10⁹/L）	HA（ng/mL）
乳腺癌组	98	50.50±10.19	5.79±1.65	0.35±0.10	71.25（55.79~96.08）
乳腺良性疾病组	37	49.35±8.26	5.86±1.18	0.36±0.13	49.36（43.83~56.13）^*
正常对照组	41	49.52±9.78	5.28±1.22	0.32±0.11	48.70（45.82~54.64）^*
组别	CA15-3（U/mL）		M1型单核细胞比例（%）	M2型单核细胞比例（%）	M2/M1比值
乳腺癌组	11.06（7.82~16.30）		30.85±5.52^#	5.71±1.52	0.193±0.070
乳腺良性疾病组	8.15（6.64~11.82）^*		39.11±4.97	3.90±0.98^*	0.087±0.028^*
正常对照组	9.82（6.75~12.09）^*		32.58±5.31^#	3.76±1.22^*	0.103±0.035^*

项目	AUC（95%可信区间）	最佳临界值	敏感性（%）	特异性（%）
HA	0.849（0.787~0.911）	61.15 ng/mL	61.22	95.12
CA15-3	0.638（0.544~0.732）	13.67 U/mL	35.71	92.68
M1型单核细胞比例	0.599（0.495~0.703）	35.35%	82.65	41.46
M2型单核细胞比例	0.852（0.779~0.923）	4.99%	71.43	87.80
M2/M1比值	0.909（0.860~0.957）	0.138	80.60	85.37
HA+ M2/M1比值联合检测	0.952（0.918~0.987）		90.82	92.68

项目	AUC（95%可信区间）	最佳临界值	敏感性（%）	特异性（%）
HA	0.849（0.787~0.911）	61.15 ng/mL	61.22	95.12
CA15-3	0.638（0.544~0.732）	13.67 U/mL	35.71	92.68
M1型单核细胞比例	0.599（0.495~0.703）	35.35%	82.65	41.46
M2型单核细胞比例	0.852（0.779~0.923）	4.99%	71.43	87.80
M2/M1比值	0.909（0.860~0.957）	0.138	80.60	85.37
HA+ M2/M1比值联合检测	0.952（0.918~0.987）		90.82	92.68

项目	AUC（95%可信区间）	最佳临界值	敏感性（%）	特异性（%）
HA	0.839（0.772~0.905）	61.17 ng/mL	60.20	89.19
CA15-3	0.631（0.529~0.733）	13.70 U/mL	34.68	83.78
M1型单核细胞比例	0.870（0.808~0.931）	35.69%	85.71	75.68
M2型单核细胞比例	0.851（0.785~0.918）	5.00%	69.39	86.49
M2/M1比值	0.960（0.911~0.984）	0.127	89.80	91.89
HA+ M2/M1比值联合检测	0.973（0.949~0.997）		91.84	97.30